Fig. 6

Dinaciclib and PLX51107 demonstrate additive effects and reduce disease burden in MOLM-13 xenograft mice. (A) 10,000 luciferase/GFP labeled MOLM-13 cells were xenografted by tail-vein injection in NSG mice, followed by a dosing schedule of PLX51107 20 mg/kg daily oral gavage, dinaciclib 10 mg/kg intraperitoneal injection once weekly, combination, or vehicle treatment (*, *** = p ≤ 0.05 and 0.005 respectively). (B) Weekly disease burden was assessed using a bioluminescent in-vivo imaging system (IVIS). Of note, one mouse in the combination arm died due to oral gavage error at week 2 and not due to leukemia burden or combination toxicity. (C) Histopathological analysis revealed the absence of previously observed microvesicular hepatic lipidosis and reduced infiltration of tissues in dinaciclib, PLX51107 and combination treatment arms when compared to vehicle treated mice